Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
MEK and Autophagy Inhibition in Metastatic/Locally Advanced Unresectable Neuroblastoma RAS (NRAS) Melanoma

Patients with metastatic Neuroblastoma RAS (NRAS) melanoma are currently treated with first line immune checkpoint inhibitors (nivolumab, pembrolizumab). Thus far, no targeted therapy has been

  • 0 views
  • 25 Jan, 2021
  • 5 locations
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS NRAS or KRAS) Positive Metastatic Colorectal Cancers

This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination

  • 0 views
  • 02 May, 2021
  • 1 location
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy in First Line With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

To assess the efficacy and safety of the combination of CPGJ602 and chemotherapy in subjects with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.

  • 0 views
  • 02 Sep, 2021
  • 1 location
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

This is a phase II trial to examine the efficacy of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (all RAS/NRAS/BRAF/PIK3CA wild-type), metastatic

PIK3CA
liver metastasis
ct scan
KRAS
metastasis
  • 114 views
  • 18 Apr, 2021
  • 48 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG)

uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment

  • 18 views
  • 16 Sep, 2021
  • 14 locations
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. To evaluate the antitumor activity of …

  • 0 views
  • 19 Sep, 2021
  • 1 location
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.

NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

cobimetinib
cancer
advanced melanoma
NRAS
malignant melanoma of skin
  • 0 views
  • 04 Sep, 2021
  • 9 locations
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, …

aflibercept
cancer
vascular endothelial growth factor
adenocarcinoma
irinotecan
  • 308 views
  • 17 Sep, 2021
  • 81 locations
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)

Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of

liver metastasis
cancer
advanced melanoma
metastasis
NRAS
  • 1 views
  • 22 Jan, 2021
Study of HL-085 in NRAS Mutant Advanced Melanoma

This is a phase I/II, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with NRAS mutant advanced melanoma .

advanced melanoma
NRAS
mek inhibitor
  • 33 views
  • 26 Jan, 2021
  • 2 locations